Appeal No. 1997-1842
Application 08/068,878
Lepor et al. (Lepor 1992), “The Safety, Efficacy and Compliance of Terazosin Therapy
for Benign Prostatic Hyperplasia,” J. Urology, 147, pp. 1554-57 (June 1992).
The references relied upon by this merits panel are set forth above and the
following:
“HYTRIN®,“ in Physicians’ Desk Reference®, 526-28 (45th ed., New Jersey, publisher
Edward R. Barnhart, 1991).
Roteman 4,251,532 Feb. 17, 1981
Kyncl et al. (Kyncl) 5,212,176 May 18, 1993
(filed June 29, 1990)
Claims 1-7 stand rejected under 35 U.S.C. § 103. The examiner relies upon
Lepor et al. 1988, Lepor et al. 1989, Lepor et al. 1992, Lepor 1989, Dunzendorfer and
Fabricius as evidence of obviousness. We vacate the examiner’s rejection and enter a
new ground of rejection under the provisions of 37 CFR § 1.196(b).
DISCUSSION
Claim 1 and claims which depend from claim 1 are directed to a method for the
chronic treatment, for a period of at least two and one-half years, of urinary symptoms
associated with benign prostatic hyperplasia (BPH). The method comprises the step of
administering to a male human patient in need of such treatment a therapeutically
effective amount of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-
furanyl)carbonyl]piperazine or a pharmaceutically-acceptable salt thereof.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007